ERBB2 and breast carcinoma: Lapatinib HER2 receptor inhibitor that inhibits the HER2 receptor’s intracellular tyrosine kinase domain and can act on both ligand-induced and ligand-independent pathways of HER2 signaling, can be given in patients with advanced and aggressive HER2/neu-positive breast cancer who have undergone previous anthracycline and trastuzumab treatment.